Sangui Biotech International Inc Revenue Growth Rates (SGBI), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Sangui Biotech International Inc  (SGBI)
 

SGBI's Revenue Growth by Quarter and Year

Sangui Biotech International Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SGBI Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter June -
3rd Quarter March 0.02
2nd Quarter December 0.01
1st Quarter September 0.04
FY 0.07

SGBIs Annual Revenue
Sangui Biotech International Inc's Revenue in the fiscal year 2022 $ 0.07 millions
Sangui Biotech International Inc's Revenue in the fiscal year 2021 $ 0.07 millions
Sangui Biotech International Inc's Revenue in the fiscal year 2020 $ 0.03 millions
Sangui Biotech International Inc's Revenue in the fiscal year 2019 $ 0.09 millions
Sangui Biotech International Inc's Revenue in the fiscal year 2018 $ 0.08 millions




SGBI Revenue third quarter 2023 Y/Y Growth Comment
Sangui Biotech International Inc reported decrease in Revenue in the third quarter 2023 by -6.52% to $ 0.02 millions, from the same quarter in 2022.
The decrease in the third quarter 2023 Sangui Biotech International Inc's Revenue compares unfavorably to the Company's average Revenue doubling of 227.24%.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 133 other companies have achieved higher Revenue growth. While Sangui Biotech International Inc' s Revenue decline of -6.52% ranks overall at the positon no. 2199 in the third quarter 2023.


SGBI Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter June - 0 % 0 % -50 %
3rd Quarter March -6.52 % 0 % 100 % 0 %
2nd Quarter December -50 % 100 % 0 % -75 %
1st Quarter September 100 % 0 % - -
FY   - 16.67 % 100 % -

Financial Statements
Sangui Biotech International Inc's third quarter 2023 Revenue $ 0.02 millions SGBI's Income Statement
Sangui Biotech International Inc's third quarter 2022 Revenue $ 0.02 millions Quarterly SGBI's Income Statement


SGBI Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter June - -50 % -50 % 0 %
3rd Quarter March 86.97 % 0 % 100 % 0 %
2nd Quarter December -75 % 0 % -50 % -
1st Quarter September 300 % 100 % 100 % -
FY (Year on Year)   - 16.67 % 100 % -


Back to SGBI Growth rate Comparisons >> Back to SGBI Growth rate Comparisons >>


Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #134
Healthcare Sector #369
Overall #2199

Revenue Y/Y Growth Statistics
High Average Low
6949.65 % 227.24 % -97.5 %
(Sep 30 2020)   (Sep 30 2019)
Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #134
Healthcare Sector #369
Overall #2199
Revenue Y/Y Growth Statistics
High Average Low
6949.65 % 227.24 % -97.5 %
(Sep 30 2020)   (Sep 30 2019)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Sangui Biotech International Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
4042.91 % 147.97 % -98.85 %
(Dec 31 2019)  


SGBI's III. Quarter Q/Q Revenue Comment
Sangui Biotech International Inc achieved in the III. Quarter 2023 below company average Revenue jump of 86.97% quarter on quarter, to $ 0.02 millions.

III. Quarter 2023 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 0% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 22 other companies have achieved higher Revenue quarter on quarter growth. While Sangui Biotech International Inc's Revenue growth quarter on quarter, overall rank is 172.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #23
Healthcare Sector #51
Overall #172
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #23
Healthcare Sector #51
Overall #172
Revenue Q/Q Growth Statistics
High Average Low
4042.91 % 147.97 % -98.85 %
(Dec 31 2019)  


SGBI's III. Quarter Q/Q Revenue Comment
Sangui Biotech International Inc achieved in the III. Quarter 2023 below company average Revenue jump of 86.97% quarter on quarter, to $ 0.02 millions.

III. Quarter 2023 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 0% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 22 other companies have achieved higher Revenue quarter on quarter growth. While Sangui Biotech International Inc's Revenue growth quarter on quarter, overall rank is 172.


Sangui Biotech International Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)
Cumulative Revenue 12 Months Ending $ 0.08 $ 0.08 $ 0.09 $ 0.07 $ 0.07
Y / Y Revenue Growth (TTM) 11.5 % 5.77 % 42.63 % 5.5 % 21.89 %
Year on Year Revenue Growth Overall Ranking # 1062 # 237 # 624 # 2444 # 1375
Seqeuential Revenue Change (TTM) 0.93 % -12.6 % 32.47 % -4.59 % -4.26 %
Seq. Revenue Growth (TTM) Overall Ranking # 2937 # 859 # 152 # 3505 # 943


Cumulative Revenue growth Comment
Sangui Biotech International Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 11.5% year on year, to $ 0 millions if the fiscal year would have ended in Mar 31 2023.
Sangui Biotech International Inc's trailing twelve months Revenue growth was higher than company's average 10.23% and higher than 5.77% growth in Dec 31 2022.
But from twelve months ended Dec 31 2022 rise was beneth at 0.93 % from $0.08 millions achieved in the period from Dec 31 2022 to Mar 31 2022.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at7.7%.
The momentum is even more impressive from twelve months ended Dec 31 2022 exhibited at 0.93 % increase from $0.08 millions in the period from Dec 31 2022 to Mar 31 2022.

In the Healthcare sector 192 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 237 to 1062.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 153
Healthcare Sector # 193
Overall # 1062

Revenue TTM Y/Y Growth Statistics
High Average Low
126.82 %
 10.23 %
-67.14 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 153
Sector # 414
S&P 500 # 2937
Cumulative Revenue growth Comment
Sangui Biotech International Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 11.5% year on year, to $ 0 millions if the fiscal year would have ended in Mar 31 2023.
Sangui Biotech International Inc's trailing twelve months Revenue growth was higher than company's average 10.23% and higher than 5.77% growth in Dec 31 2022.
But from twelve months ended Dec 31 2022 rise was beneth at 0.93 % from $0.08 millions achieved in the period from Dec 31 2022 to Mar 31 2022.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at7.7%.
The momentum is even more impressive from twelve months ended Dec 31 2022 exhibited at 0.93 % increase from $0.08 millions in the period from Dec 31 2022 to Mar 31 2022.

In the Healthcare sector 192 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 237 to 1062.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 153
Healthcare Sector # 193
Overall # 1062

Revenue TTM Y/Y Growth Statistics
High Average Low
126.82 %
10.23 %
-67.14 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 153
Sector # 414
S&P 500 # 2937




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
SGBI's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Mar 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2023
Regenerx Biopharmaceuticals inc -0.01%$ -0.005 millions
Community Health Systems Inc -0.10%$ -0.096 millions
West Pharmaceutical Services Inc -0.47%$ -0.472 millions
Butterfly Network Inc -0.63%$ -0.629 millions
Qhslab Inc -0.71%$ -0.712 millions
Waters Corporation-0.85%$ -0.854 millions
Dariohealth Corp -0.86%$ -0.856 millions
Fresenius Medical Care Ag-1.06%$ -1.058 millions
Acorda Therapeutics Inc -1.22%$ -1.225 millions
Baxter International Inc -1.56%$ -1.565 millions
Kymera Therapeutics Inc -1.62%$ -1.621 millions
Nature s Sunshine Products inc -1.68%$ -1.683 millions
Organon and Co -1.85%$ -1.851 millions
Scientific Industries Inc -2.08%$ -2.077 millions
Amgen Inc -2.13%$ -2.132 millions
Healthcare Services Group Inc -2.24%$ -2.245 millions
Adaptive Biotechnologies Corporation-2.52%$ -2.519 millions
Bristol myers Squibb Company-2.67%$ -2.670 millions
Caredx Inc -2.71%$ -2.712 millions
Biogen Inc -2.72%$ -2.717 millions
Innovage Holding Corp -2.72%$ -2.718 millions
Cardiff Lexington Corporation-2.73%$ -2.727 millions
Apyx Medical Corp-2.81%$ -2.810 millions
Avanos Medical Inc -2.89%$ -2.888 millions
Align Technology inc -3.09%$ -3.090 millions
Bio rad Laboratories Inc -3.32%$ -3.317 millions
Enhabit Inc -3.35%$ -3.354 millions
National Healthcare Corp-3.38%$ -3.377 millions
Thermogenesis Holdings Inc -3.42%$ -3.417 millions
Mesoblast Limited-3.58%$ -3.580 millions


About Sangui Biotech International Inc Revenue Growth Rates (SGBI), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Sangui Biotech International Inc (CIK 1104280).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001096906-23-001042
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Sangui Biotech International Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.